Tryptase mast cell density, protease-activated receptor-2 microvascular density, and classical microvascular density evaluation in gastric cancer patients undergoing surgery: Possible translational relevance

Michele Ammendola, Rosario Sacco, Giuseppina Vescio, Valeria Zuccalà, Maria Luposella, Rosa Patruno, Nicola Zizzo, Claudia Gadaleta, Ilaria Marech, Roberta Ruggieri, Ibrahim Furkan Kocak, Taner Ozgurtas, Cosmo Damiano Gadaleta, Giuseppe Sammarco, Girolamo Ranieri

Research output: Contribution to journalArticle

Abstract

Background: Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosphorylation. Nevertheless, no data are available concerning the relationship among tryptase MC density (TMCD), endothelial cells (ECs) positive to PAR-2 microvascular density (PAR-2-MVD) and classical MVD (C-MVD) in gastric cancer (GC) angiogenesis. Methods: In this study, we analyzed the correlation of TMCD, PAR-2-MVD, C-MVD with each other and with the main clinicopathological features in GC patients who underwent surgery. A series of 77 GC patients with stage T2-3N2-3M0 (classified by the American Joint Committee on Cancer for Gastric Cancer, 7th edition) were selected and then underwent surgery. Results: Tumour tissue samples were evaluated by mean of immunohistochemistry and image analysis methods in terms of numbers of TMCD, PAR-2-MVD and C-MVD. A significant correlation between the TMCD, PAR-2-MVD and C-MVD groups with each other was found by Pearson t-test analysis (r ranged from 0.64 to 0.76; p value ranged from 0.02 to 0.03). There was no other significant correlation between the above parameters and clinicopathological features. Conclusions: Our in vivo preliminary data suggest that TMCD and PAR-2-MVD may play a role in GC angiogenesis and they could be further evaluated as a target of antiangiogenic therapy.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalTherapeutic Advances in Gastroenterology
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

PAR-2 Receptor
Tryptases
Stomach Neoplasms
Cell Count
Mast Cells
Mitogen-Activated Protein Kinases
Cytoplasm
Endothelial Cells
Immunohistochemistry
Phosphorylation
Cytokines

Keywords

  • Angiogenesis
  • Gastric cancer
  • Mast cells
  • PAR-2
  • Tryptase

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Tryptase mast cell density, protease-activated receptor-2 microvascular density, and classical microvascular density evaluation in gastric cancer patients undergoing surgery : Possible translational relevance. / Ammendola, Michele; Sacco, Rosario; Vescio, Giuseppina; Zuccalà, Valeria; Luposella, Maria; Patruno, Rosa; Zizzo, Nicola; Gadaleta, Claudia; Marech, Ilaria; Ruggieri, Roberta; Kocak, Ibrahim Furkan; Ozgurtas, Taner; Gadaleta, Cosmo Damiano; Sammarco, Giuseppe; Ranieri, Girolamo.

In: Therapeutic Advances in Gastroenterology, Vol. 10, No. 4, 01.04.2017, p. 353-360.

Research output: Contribution to journalArticle

Ammendola, Michele ; Sacco, Rosario ; Vescio, Giuseppina ; Zuccalà, Valeria ; Luposella, Maria ; Patruno, Rosa ; Zizzo, Nicola ; Gadaleta, Claudia ; Marech, Ilaria ; Ruggieri, Roberta ; Kocak, Ibrahim Furkan ; Ozgurtas, Taner ; Gadaleta, Cosmo Damiano ; Sammarco, Giuseppe ; Ranieri, Girolamo. / Tryptase mast cell density, protease-activated receptor-2 microvascular density, and classical microvascular density evaluation in gastric cancer patients undergoing surgery : Possible translational relevance. In: Therapeutic Advances in Gastroenterology. 2017 ; Vol. 10, No. 4. pp. 353-360.
@article{9f808fc796994b36924d4fcd5d54c72d,
title = "Tryptase mast cell density, protease-activated receptor-2 microvascular density, and classical microvascular density evaluation in gastric cancer patients undergoing surgery: Possible translational relevance",
abstract = "Background: Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosphorylation. Nevertheless, no data are available concerning the relationship among tryptase MC density (TMCD), endothelial cells (ECs) positive to PAR-2 microvascular density (PAR-2-MVD) and classical MVD (C-MVD) in gastric cancer (GC) angiogenesis. Methods: In this study, we analyzed the correlation of TMCD, PAR-2-MVD, C-MVD with each other and with the main clinicopathological features in GC patients who underwent surgery. A series of 77 GC patients with stage T2-3N2-3M0 (classified by the American Joint Committee on Cancer for Gastric Cancer, 7th edition) were selected and then underwent surgery. Results: Tumour tissue samples were evaluated by mean of immunohistochemistry and image analysis methods in terms of numbers of TMCD, PAR-2-MVD and C-MVD. A significant correlation between the TMCD, PAR-2-MVD and C-MVD groups with each other was found by Pearson t-test analysis (r ranged from 0.64 to 0.76; p value ranged from 0.02 to 0.03). There was no other significant correlation between the above parameters and clinicopathological features. Conclusions: Our in vivo preliminary data suggest that TMCD and PAR-2-MVD may play a role in GC angiogenesis and they could be further evaluated as a target of antiangiogenic therapy.",
keywords = "Angiogenesis, Gastric cancer, Mast cells, PAR-2, Tryptase",
author = "Michele Ammendola and Rosario Sacco and Giuseppina Vescio and Valeria Zuccal{\`a} and Maria Luposella and Rosa Patruno and Nicola Zizzo and Claudia Gadaleta and Ilaria Marech and Roberta Ruggieri and Kocak, {Ibrahim Furkan} and Taner Ozgurtas and Gadaleta, {Cosmo Damiano} and Giuseppe Sammarco and Girolamo Ranieri",
year = "2017",
month = "4",
day = "1",
doi = "10.1177/1756283X16673981",
language = "English",
volume = "10",
pages = "353--360",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Tryptase mast cell density, protease-activated receptor-2 microvascular density, and classical microvascular density evaluation in gastric cancer patients undergoing surgery

T2 - Possible translational relevance

AU - Ammendola, Michele

AU - Sacco, Rosario

AU - Vescio, Giuseppina

AU - Zuccalà, Valeria

AU - Luposella, Maria

AU - Patruno, Rosa

AU - Zizzo, Nicola

AU - Gadaleta, Claudia

AU - Marech, Ilaria

AU - Ruggieri, Roberta

AU - Kocak, Ibrahim Furkan

AU - Ozgurtas, Taner

AU - Gadaleta, Cosmo Damiano

AU - Sammarco, Giuseppe

AU - Ranieri, Girolamo

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background: Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosphorylation. Nevertheless, no data are available concerning the relationship among tryptase MC density (TMCD), endothelial cells (ECs) positive to PAR-2 microvascular density (PAR-2-MVD) and classical MVD (C-MVD) in gastric cancer (GC) angiogenesis. Methods: In this study, we analyzed the correlation of TMCD, PAR-2-MVD, C-MVD with each other and with the main clinicopathological features in GC patients who underwent surgery. A series of 77 GC patients with stage T2-3N2-3M0 (classified by the American Joint Committee on Cancer for Gastric Cancer, 7th edition) were selected and then underwent surgery. Results: Tumour tissue samples were evaluated by mean of immunohistochemistry and image analysis methods in terms of numbers of TMCD, PAR-2-MVD and C-MVD. A significant correlation between the TMCD, PAR-2-MVD and C-MVD groups with each other was found by Pearson t-test analysis (r ranged from 0.64 to 0.76; p value ranged from 0.02 to 0.03). There was no other significant correlation between the above parameters and clinicopathological features. Conclusions: Our in vivo preliminary data suggest that TMCD and PAR-2-MVD may play a role in GC angiogenesis and they could be further evaluated as a target of antiangiogenic therapy.

AB - Background: Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosphorylation. Nevertheless, no data are available concerning the relationship among tryptase MC density (TMCD), endothelial cells (ECs) positive to PAR-2 microvascular density (PAR-2-MVD) and classical MVD (C-MVD) in gastric cancer (GC) angiogenesis. Methods: In this study, we analyzed the correlation of TMCD, PAR-2-MVD, C-MVD with each other and with the main clinicopathological features in GC patients who underwent surgery. A series of 77 GC patients with stage T2-3N2-3M0 (classified by the American Joint Committee on Cancer for Gastric Cancer, 7th edition) were selected and then underwent surgery. Results: Tumour tissue samples were evaluated by mean of immunohistochemistry and image analysis methods in terms of numbers of TMCD, PAR-2-MVD and C-MVD. A significant correlation between the TMCD, PAR-2-MVD and C-MVD groups with each other was found by Pearson t-test analysis (r ranged from 0.64 to 0.76; p value ranged from 0.02 to 0.03). There was no other significant correlation between the above parameters and clinicopathological features. Conclusions: Our in vivo preliminary data suggest that TMCD and PAR-2-MVD may play a role in GC angiogenesis and they could be further evaluated as a target of antiangiogenic therapy.

KW - Angiogenesis

KW - Gastric cancer

KW - Mast cells

KW - PAR-2

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=85018159652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018159652&partnerID=8YFLogxK

U2 - 10.1177/1756283X16673981

DO - 10.1177/1756283X16673981

M3 - Article

AN - SCOPUS:85018159652

VL - 10

SP - 353

EP - 360

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 4

ER -